Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Settings
Settings
Dynamic quotes 
OFFON

MarketScreener Homepage  >  Equities  >  Nasdaq  >  Henry Schein, Inc.    HSIC

HENRY SCHEIN, INC.

(HSIC)
  Report
SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
News SummaryMost relevantAll newsPress ReleasesOfficial PublicationsSector newsAnalyst Recommendations

Shareholder Alert: Robbins LLP Announces Complaint Filed Against Henry Schein, Inc. (HSIC)

share with twitter share with LinkedIn share with facebook
share via e-mail
0
11/21/2019 | 07:59pm EST

Shareholder rights law firm Robbins LLP announces that a purchaser of Henry Schein, Inc. (NASDAQ: HSIC) has filed a shareholder derivative complaint against the Company's officers and directors for breaches of fiduciary duties, unjust enrichment, abuse of control, gross mismanagement, waste of corporate assets, and alleged violations of the Securities Exchange Act of 1934. Henry Schein is purportedly the largest health care provider in the world.

If you suffered a loss as a result of Henry Schein's misconduct, click here.

Henry Schein, Inc. (HSIC) Accused of Antitrust and Securities Violations

According to the complaint, between March 2013 and February 2018, the executives of Henry Schein engaged in a conspiracy with Benco and Patterson to restrain trade to drive down competition in the dental products market and inflate the prices of dental products. This agreement included refusing to offer discounted prices or to negotiate with group purchasing organizations, refraining from poaching one another's customers or sales representatives, and blocking the entry and expansion of rival distributors. The conspiracy came to light on February 12, 2018, when the Federal Trade Commission filed an administrative complaint against Henry Schein, Benco, and Patterson for violation of federal antitrust law. Additionally, multiple dental and medical suppliers have brought lawsuits against Henry Schein alleging antitrust violations.

On February 8, 2019, Henry Schein's newly merged animal healthcare business Covetrus began trading on NASDAQ. Henry Schein's officers and directors touted the Company's financial prospects. However, on August 13, 2019, Covetrus shockingly reported disappointing financial results and reduced EBITDA, causing its stock price to plummet. The stock has yet to recover and Covetrus shareholders have brought a lawsuit to recover their losses.

Henry Schein, Inc. (HSIC) Shareholders Have Legal Options

Contact us to learn more:
Leo Kandinov
(800) 350-6003
lkandinov@robbinsllp.com
Shareholder Information Form

Robbins LLP is a nationally recognized leader in shareholder rights law. The firm represents individual and institutional investors in shareholder derivative and securities class action lawsuits, and has helped its clients realize more than $1 billion of value for themselves and the companies in which they have invested. Click here to receive free alerts from Stock Watch when companies engage in wrongdoing.

Attorney Advertising. Past results do not guarantee a similar outcome.


© Business Wire 2019
share with twitter share with LinkedIn share with facebook
share via e-mail
0
Latest news on HENRY SCHEIN, INC.
01/13HENRY SCHEIN : Opens Disaster Relief Fund to Aid Relief Efforts in Response to A..
BU
01/08SHAREHOLDER ALERT : Robbins LLP Is Investigating Henry Schein, Inc. (HSIC) for V..
BU
2019HENRY SCHEIN INC : Regulation FD Disclosure (form 8-K)
AQ
2019HENRY SCHEIN : to Present at the 38th Annual J.P. Morgan Healthcare Conference
BU
2019HENRY SCHEIN : Celebrates 21st Annual ‘Holiday Cheer for Children' Program..
BU
2019HENRY SCHEIN : and the National Council on Disability Ally to Improve Access to ..
BU
2019HENRY SCHEIN : Chairman and CEO Stanley M. Bergman Honored for Advancing Diversi..
BU
2019SHAREHOLDER ALERT : Robbins LLP Announces Complaint Filed Against Henry Schein, ..
BU
2019HENRY SCHEIN : to Present New Products and Solutions, Educational Offerings, and..
BU
2019HENRY SCHEIN : to Present at Nasdaq's 41st Investor Conference
BU
More news
Financials (USD)
Sales 2019 9 959 M
EBIT 2019 725 M
Net income 2019 500 M
Debt 2019 1 003 M
Yield 2019 -
P/E ratio 2019 20,6x
P/E ratio 2020 18,8x
EV / Sales2019 1,12x
EV / Sales2020 1,07x
Capitalization 10 168 M
Chart HENRY SCHEIN, INC.
Duration : Period :
Henry Schein, Inc. Technical Analysis Chart | MarketScreener
Full-screen chart
Technical analysis trends HENRY SCHEIN, INC.
Short TermMid-TermLong Term
TrendsNeutralBullishNeutral
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus HOLD
Number of Analysts 19
Average target price 68,31  $
Last Close Price 69,29  $
Spread / Highest target 15,5%
Spread / Average Target -1,41%
Spread / Lowest Target -19,2%
EPS Revisions
Managers
NameTitle
Stanley M. Bergman Chairman & Chief Executive Officer
James P. Breslawski Vice Chairman & President
Steven Paladino Chief Financial Officer, Director & Executive VP
Christopher Pendergast Chief Technology Officer & Senior Vice President
Philip A. Laskaway Lead Independent Director
Sector and Competitors
1st jan.Capitalization (M$)
HENRY SCHEIN, INC.3.85%10 168
CANTEL MEDICAL CORP.-11.90%2 631
PATTERSON COMPANIES13.67%2 197
SHIP HEALTHCARE HOLDINGS, INC.1.72%2 176
MERIT MEDICAL SYSTEMS, INC.17.55%2 026
AS ONE CORPORATION2.10%1 732